Based in North Carolina, Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on developing PEDMARK, a sodium thiosulfate formulation to prevent platinum-induced ototoxicity in pediatric cancer patients, currently in the clinical stage. Founded in 1996, the company was previously known as Adherex Technologies Inc. and changed its name in 2014.